Jump to content

Duligotuzumab

From Wikipedia, the free encyclopedia
(Redirected from Duligotumab)
Duligotuzumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetHER3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG

Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.[2]

References

[edit]
  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
  2. ^ "Duligotuzumab". AdisInsight.


pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy